Sartorius is focused on providing its customers in the biopharmaceutical industry as well as at biotech start-ups and in science the tools and technologies to achieve such breakthroughs, enabling researchers, developers, and engineers to reach their goals faster and at lower costs. We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. We are a magnet and dynamic platform for pioneers and leading experts in our field. We bring creative minds together for a common goal: technological breakthroughs that lead to better health for more people.
Sartorius acquired BIA Separations in 2020, already developing and manufacturing market-leading CIM® monolithic columns for purification and analysis of large biomolecules such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. The technology for manufacturing scale purification has been used in the production of the first commercialized advanced therapeutics. Sartorius maintains a keen presence for novel drug candidates in the clinical pipeline.
In 2021, sales revenue rose to around €3.45billion, not only due to our contributions in producing newly developed coronavirus vaccines and test kits at an unparalleled speed and in unprecedented quantities. Our core business generated even higher contributions to our growth, achieving new record highs in all product segments, and in all geographies. At the close of 2021, Sartorius was proud to be working alongside almost 14,000 global employees. Investments totalled around €400million and were used to expand our capacities in several product segments and in all business regions.
www.sartorius.comÂ
